Bicocca Open Archive

Logo unimib boa
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 34.171
AS - Asia 25.287
EU - Europa 14.339
SA - Sud America 3.720
AF - Africa 509
OC - Oceania 68
Continente sconosciuto - Info sul continente non disponibili 30
AN - Antartide 1
Totale 78.125
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.159
SG - Singapore 8.308
CN - Cina 4.638
IT - Italia 4.512
VN - Vietnam 4.075
HK - Hong Kong 3.801
BR - Brasile 2.840
RU - Federazione Russa 2.579
CA - Canada 1.711
BD - Bangladesh 1.596
IE - Irlanda 1.395
UA - Ucraina 1.086
SE - Svezia 991
DE - Germania 912
GB - Regno Unito 674
FR - Francia 644
IN - India 528
FI - Finlandia 487
KR - Corea 430
ID - Indonesia 380
AR - Argentina 351
AT - Austria 280
JP - Giappone 234
NL - Olanda 222
TR - Turchia 213
IQ - Iraq 191
ZA - Sudafrica 166
MX - Messico 154
EC - Ecuador 149
PK - Pakistan 136
SA - Arabia Saudita 109
ES - Italia 108
PH - Filippine 94
CO - Colombia 89
VE - Venezuela 82
MA - Marocco 81
UZ - Uzbekistan 81
PY - Paraguay 66
DK - Danimarca 63
TW - Taiwan 60
CL - Cile 58
KE - Kenya 57
AU - Australia 55
EG - Egitto 53
MY - Malesia 52
PL - Polonia 48
CH - Svizzera 40
TH - Thailandia 35
JO - Giordania 34
NP - Nepal 34
RO - Romania 34
TN - Tunisia 34
BE - Belgio 33
PE - Perù 33
AE - Emirati Arabi Uniti 32
DZ - Algeria 31
JM - Giamaica 28
CR - Costa Rica 27
IR - Iran 27
AZ - Azerbaigian 26
BG - Bulgaria 25
UY - Uruguay 25
CZ - Repubblica Ceca 23
ET - Etiopia 21
IL - Israele 21
LB - Libano 21
RS - Serbia 21
BO - Bolivia 20
EU - Europa 20
LT - Lituania 20
OM - Oman 20
PT - Portogallo 20
AL - Albania 17
GR - Grecia 17
KZ - Kazakistan 17
NO - Norvegia 17
HN - Honduras 16
SN - Senegal 16
GT - Guatemala 13
NI - Nicaragua 13
PS - Palestinian Territory 13
QA - Qatar 12
DO - Repubblica Dominicana 11
SY - Repubblica araba siriana 11
HU - Ungheria 10
TT - Trinidad e Tobago 10
KG - Kirghizistan 9
MD - Moldavia 9
NZ - Nuova Zelanda 9
AO - Angola 8
BY - Bielorussia 8
GE - Georgia 8
HR - Croazia 8
PA - Panama 8
SV - El Salvador 8
A2 - ???statistics.table.value.countryCode.A2??? 7
BA - Bosnia-Erzegovina 6
KW - Kuwait 6
MK - Macedonia 6
MT - Malta 6
Totale 78.002
Salva come PNG Salva come JPEG
Città #
Singapore 4.388
Hong Kong 3.746
Ann Arbor 3.338
Woodbridge 2.685
Ashburn 2.484
Fairfield 2.358
Houston 1.925
San Jose 1.459
Dublin 1.310
Toronto 1.270
Ho Chi Minh City 1.232
Milan 1.214
Jacksonville 1.202
Wilmington 1.028
New York 992
Hanoi 945
Seattle 915
Hefei 867
Cambridge 787
Chicago 771
Dearborn 737
Chandler 696
The Dalles 657
Princeton 639
Santa Clara 598
Los Angeles 479
Rome 469
Beijing 423
Dallas 419
Lauterbourg 406
Seoul 388
Frankfurt am Main 375
Council Bluffs 339
Lawrence 315
Moscow 309
Altamura 290
Nanjing 285
Buffalo 266
Jakarta 258
São Paulo 233
Helsinki 215
Lachine 202
Vienna 200
Guangzhou 183
Boardman 178
Shanghai 165
Haiphong 163
Da Nang 147
Nuremberg 144
San Diego 144
Tokyo 130
London 126
Andover 125
Naples 112
Dong Ket 96
Turin 95
Rio de Janeiro 89
Nanchang 88
Biên Hòa 86
Salt Lake City 79
Shenyang 76
Tashkent 76
Hamburg 75
Tianjin 75
Changsha 74
Figino 73
Phoenix 70
Falls Church 69
Dhaka 67
Quận Bình Thạnh 62
Ha Long 61
Hải Dương 61
Ottawa 61
Columbus 60
Hebei 60
Johannesburg 59
Ninh Bình 57
Baghdad 56
Orem 56
Norwalk 53
Can Tho 52
Guayaquil 52
Hangzhou 52
Lahore 50
Tampa 50
Thái Nguyên 50
Mountain View 49
Curitiba 48
Lappeenranta 48
Miami 48
Nairobi 48
Quito 48
Brasília 47
Chennai 47
Elk Grove Village 47
Riyadh 47
Atlanta 46
Jiaxing 45
Kent 45
Amsterdam 43
Totale 48.527
Salva come PNG Salva come JPEG
Nome #
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial 616
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up 613
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 580
Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma 426
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 390
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 364
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer 361
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer 357
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 353
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 352
Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference 348
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 345
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells 335
FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer 302
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 297
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 286
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 285
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer 283
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial 281
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer 281
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial 280
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 279
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 273
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study 273
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 258
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study 257
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 256
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation 252
Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors 252
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 251
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 249
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial 247
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics 245
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study 243
Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes 243
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells 242
Neoadjuvant chemotherapy in cervical cancer: An update 242
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients 240
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025 239
The disposition of carboplatin in ovarian cancer patients 238
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial 235
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 235
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer 235
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer 234
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 233
Sentinel lymph node biopsy in pregnant patients with breast cancer 232
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 231
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 231
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin 230
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 230
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup 228
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 226
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial 226
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial 226
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial 223
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites 223
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 223
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 223
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 223
Reply to M.L. Friedlander et al 222
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 222
Hydrological, thermal and chemical influence of an intact rock glacier discharge on mountain stream water 220
The role of surgery in gestational trophoblastic disease 220
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 220
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 219
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval 219
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 219
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial 219
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 219
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge 218
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 217
Trabectedin as single agent in relapsed advanced ovarian cancer: Results from a retrospective pooled analysis of three phase II trials 217
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial 216
Chemo-conization in early cervical cancer 215
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 215
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 215
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 215
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 215
Low-dose oral etoposide in epithelial cancer of the ovary 214
Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum 214
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 213
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 213
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study 213
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease 212
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 212
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 212
A reassessment of the role of second-look laparotomy in advanced ovarian cancer 212
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 212
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status 211
Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ 210
DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response 210
Are monoclonal antibodies a safe treatment for cancer during pregnancy? 210
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells 209
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study 209
Aggressive angiomyxoma of the vulva 208
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion 207
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 207
Roadmap for the european network of gynaecological trial groups (ENGOT) trials 206
External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma 206
Reduction of postoperative complication rate with the use of early oral feeding in gynecologic oncologic patients undergoing a Major surgery: A randomized controlled trial 206
Totale 25.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 265.027
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 265.027
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.002 181 245 348 237 184 196 168 209 186 250 231 567
2022/20234.033 665 1.028 274 226 247 729 59 327 243 66 95 74
2023/20244.164 98 105 176 111 637 1.033 755 107 525 117 68 432
2024/202513.024 713 1.688 492 616 1.039 526 998 405 1.286 1.616 1.088 2.557
2025/202634.535 3.666 3.062 2.373 3.235 2.689 1.547 3.834 1.853 2.529 2.559 3.118 4.070
2026/2027967 967 0 0 0 0 0 0 0 0 0 0 0
Totale 79.556